Merck & Co., Inc. (MRK) Stock Price & Analysis
Merck & Co., Inc. (MRK) rose 0.45% to USD 131.07 as of July 25, 2026 at 01:13 UTC, according to Nexqual real-time market data.
MRK last closed at USD 130.48; the session ranged USD 130.24–131.71 on volume of 4,540,145 shares. Market capitalization is —, with a 52-week range of USD 76.66–131.74 (NYQ). Source: Nexqual, July 25, 2026 at 01:13 UTC.
Key Statistics (as of July 25, 2026 at 01:13 UTC)
| Price | USD 131.07 |
|---|---|
| Change | ▲ 0.45% (up) |
| Previous Close | USD 130.48 |
| Open | USD 131.44 |
| Day Range | USD 130.24 – 131.71 |
| 52-Week Range | USD 76.66 – 131.74 |
| Volume | 4,540,145 shares |
| Market Cap | — |
| Exchange | NYQ |
Technical Analysis (MRK)
Nexqual's technical model rates MRK "BUY" based on 5 bullish and 1 bearish signals across 125 daily candles, as of July 25, 2026 at 01:13 UTC.
| Overall Signal | BUY |
|---|---|
| RSI (14) | 60.78 (neutral) |
| vs SMA50 | Above (USD 121.1) |
| MACD | 2.13 (positive) |
Analyst Ratings (MRK)
Wall Street analysts rate MRK "Buy" based on 26 analysts, with a mean price target of USD 134.62 (range USD 100–155), per Nexqual as of July 25, 2026 at 01:13 UTC.
| Consensus Rating | Buy |
|---|---|
| Analyst Count | 26 |
| Mean Target | USD 134.62 |
| High Target | USD 155 |
| Low Target | USD 100 |
| Buy / Hold / Sell | 19 / 8 / 1 |
Earnings (MRK)
| Next Earnings Date | 2026-08-04 |
|---|---|
| EPS Estimate | USD -0.26 |
| Revenue Estimate | $16.37B |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-03-31 | USD -1.28 vs est -1.47 ▲ beat |
| 2025-12-31 | USD 2.04 vs est 2.01 ▲ beat |
| 2025-09-30 | USD 2.58 vs est 2.35 ▲ beat |
| 2025-06-30 | USD 2.13 vs est 2.03 ▲ beat |
Source: Nexqual, July 25, 2026 at 01:13 UTC.
Financials & Fundamentals (MRK)
| Total Revenue | $65.77B |
|---|---|
| Revenue Growth (YoY) | +4.90% |
| Gross Margin | +76.73% |
| Operating Margin | +38.60% |
| Profit Margin | +13.59% |
| ROE | +18.94% |
| Debt / Equity | 106.94 |
| Current Ratio | 1.3 |
| Total Cash | $5.70B |
| Total Debt | $49.12B |
| Free Cash Flow | $14.05B |
Source: Nexqual, July 25, 2026 at 01:13 UTC.
Financial Health Score (MRK)
Nexqual rates Merck & Co., Inc.'s overall financial health "Solid" across five dimensions, as of July 25, 2026 at 01:13 UTC.
| Growth | Mixed — Revenue +4.9% YoY (latest Q), slow |
|---|---|
| Profitability | Strong — Gross margin 77%, operating 39% |
| Balance Sheet | Mixed — $5.70B cash vs $49.1B debt |
| Cash Flow | Strong — FCF $14.0B, 21% margin |
| Efficiency | Solid — ROE 19%, ROA 12.6% |
Ownership (MRK)
| Insider Ownership | +0.06% |
|---|---|
| Institutional Ownership | +82.23% |
| Float | 2.47B |
| Short % of Float | +1.27% |
Source: Nexqual, July 25, 2026 at 01:13 UTC.
Leadership (MRK)
Merck & Co., Inc. is led by Robert M. Davis (age 58), Chairman, President & CEO, per Nexqual as of July 25, 2026 at 01:13 UTC.
| Chairman, President & CEO | Robert M. Davis (age 58) |
|---|---|
| Executive VP & CFO | Caroline A. Litchfield (age 56) |
| Executive VP & President of Merck Research Laboratories | Dean Y. Li (age 62) |
| Vice President of Investor Relations | Peter Dannenbaum |
| Executive Vice President of Strategic Access, Policy & Communications | Chirfi Guindo (age 59) |
Major Backers & Investors (MRK)
Notable institutional backers of Merck & Co., Inc. include Wellington Management, JPMorgan, Charles Schwab Investment Management, Inc., according to Nexqual as of July 25, 2026 at 01:13 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Wellington Management | 3.41% |
| JPMorgan | 2.14% |
| Charles Schwab Investment Management, Inc. | 2.01% |
| Morgan Stanley | 1.93% |
| FMR, LLC | 1.8% |
| Fidelity | 1.29% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Vanguard Group | 17.22% |
| BlackRock | 10.46% |
| State Street | 6.04% |
| Geode Capital | 2.41% |
Source: Nexqual, July 25, 2026 at 01:13 UTC.
From Merck & Co., Inc.'s Latest SEC 10-K Filing (filed 2026-02-24)
Key Strengths & Strategy (as disclosed to the SEC)
- Department of Health and Human Services (HHS) has stated that immunizations for all of the diseases covered by the previous immunization schedule will still be available to anyone who wants them through Affordable Care Act insurance plans and federal insurance programs, including Medicaid, the Children's Health Insurance Program, and the VFC program.
Partnerships
- The Company manufactures a hepatitis B vaccine ( Recombivax HB , Hepatitis B Vaccine [Recombinant]) and, subject to a collaboration agreement with Sanofi Pasteur MSD, co-promotes a hexavalent vaccine that includes a hepatitis B component ( Vaxelis, Diphtheria and Tetanus Toxoids and Acellular Pertussis, Inactivated Poliovirus, Haemophilus b Conjugate and Hepatitis B Vaccine).
- Product Approvals Set forth below is a summary of significant product approvals received by the Company in 2025 and, to date, in 2026. 4 Table of Contents 5 Table of Contents (1)      Keytruda Qlex is available in some markets as Keytruda SC . (2)     Being jointly developed and commercialized in a worldwide collaboration with AstraZeneca.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| PFE | Pfizer, Inc. | USD 24.54 | ▼ 1.13% |
| JNJ | Johnson & Johnson | USD 263.4 | ▲ 3.04% |
| PG | Procter & Gamble Company (The) | USD 147.41 | ▼ 1.15% |
| BMY | Bristol-Myers Squibb Company | USD 62.09 | ▲ 2.19% |
| VZ | Verizon Communications Inc. | USD 46.38 | ▲ 4.72% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: July 25, 2026 at 01:13 UTC. This page is informational and not investment advice.